Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 97.7% in May

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 18,505 shares, a drop of 97.7% from the April 30th total of 802,992 shares. Based on an average trading volume of 318,127 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Provectus Biopharmaceuticals Price Performance

Shares of PVCT stock traded up $0.00 on Thursday, reaching $0.06. 17,131 shares of the company’s stock were exchanged, compared to its average volume of 283,121. Provectus Biopharmaceuticals has a 52 week low of $0.04 and a 52 week high of $0.11. The company’s fifty day simple moving average is $0.06 and its 200 day simple moving average is $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.